Search

Displaying results 2341 - 2350 of 10000 in total
  1. Drug

    Meprobamate

    go.drugbank.com/drugs/DB00371
    ApprovedIllicit

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S. … It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines.

  2. Drug

    Insulin beef

    go.drugbank.com/drugs/DB09456
    Approved

    Insulin beef has been discontinued in the US and Canada since 2017.[L10827]

    Categories: Drugs Used in Diabetes
  3. Drug

    Ketamine

    go.drugbank.com/drugs/DB01221
    ApprovedInvestigationalVet approved

    It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332] … Ketamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories.

    Categories: N-Methylaspartate, agonists, N-Methylaspartate, antagonists & inhibitorsProducts: Ketamin G.L. 10 mg/ml - Injektions-/Infusionslösung in Ampullen, Ketamin G.L. 50 mg/ml - Injektions-/Infusionslösung in Ampullen
  4. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. … Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.

    Synonyms: N-cyclobutylmethyl-4,5α-epoxy-3,6α,14-morphinantriol
  5. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.

  6. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States. … Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ).

  7. Drug

    Pembrolizumab

    go.drugbank.com/drugs/DB09037
    ApprovedInvestigational

    [A7624] In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers. … [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026]

  8. Drug

    Molindone

    go.drugbank.com/drugs/DB01618
    Approved

    An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder.

  9. Drug

    Astemizole

    go.drugbank.com/drugs/DB00637
    ApprovedWithdrawn

    Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. … It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.

  10. Drug

    Damoctocog alfa pegol

    go.drugbank.com/drugs/DB14700
    ApprovedInvestigational

    [L4576,A38909] This product has been engineered by Bayer[L4576] and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018.[F1609] … In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval.